Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -352.08 Million USD | -51.89% |
| 2022 | -231.8 Million USD | 39.7% |
| 2021 | -384.41 Million USD | -17.43% |
| 2020 | -327.37 Million USD | 20.44% |
| 2019 | -411.47 Million USD | -18.91% |
| 2018 | -346.02 Million USD | -9.97% |
| 2017 | -314.67 Million USD | -58.55% |
| 2016 | -198.47 Million USD | -68.58% |
| 2015 | -117.73 Million USD | -120.04% |
| 2014 | -53.5 Million USD | -22.8% |
| 2013 | -43.56 Million USD | -59.64% |
| 2012 | -27.29 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -96.11 Million USD | -17.87% |
| 2024 Q3 | 947.91 Million USD | 1086.2% |
| 2024 Q1 | -81.54 Million USD | 15.0% |
| 2023 Q1 | -81.01 Million USD | -321.81% |
| 2023 Q4 | -95.94 Million USD | -5.05% |
| 2023 FY | -352.08 Million USD | -51.89% |
| 2023 Q3 | -91.32 Million USD | -8.97% |
| 2023 Q2 | -83.8 Million USD | -3.44% |
| 2022 Q3 | -81.74 Million USD | 10.96% |
| 2022 FY | -231.8 Million USD | 39.7% |
| 2022 Q4 | 36.52 Million USD | 144.68% |
| 2022 Q2 | -91.8 Million USD | 3.13% |
| 2022 Q1 | -94.77 Million USD | -0.16% |
| 2021 Q1 | -118.22 Million USD | -39.84% |
| 2021 Q2 | -83.41 Million USD | 29.44% |
| 2021 Q3 | -88.14 Million USD | -5.67% |
| 2021 Q4 | -94.62 Million USD | -7.35% |
| 2021 FY | -384.41 Million USD | -17.43% |
| 2020 Q4 | -84.54 Million USD | -6.78% |
| 2020 Q1 | -84.09 Million USD | 17.84% |
| 2020 Q2 | -81.49 Million USD | 3.09% |
| 2020 FY | -327.37 Million USD | 20.44% |
| 2020 Q3 | -79.17 Million USD | 2.85% |
| 2019 FY | -411.47 Million USD | -18.91% |
| 2019 Q4 | -102.35 Million USD | 3.6% |
| 2019 Q2 | -109.87 Million USD | -18.04% |
| 2019 Q3 | -106.17 Million USD | 3.37% |
| 2019 Q1 | -93.07 Million USD | -1.4% |
| 2018 Q2 | -68.74 Million USD | 24.31% |
| 2018 FY | -346.02 Million USD | -9.97% |
| 2018 Q4 | -91.79 Million USD | 3.03% |
| 2018 Q3 | -94.66 Million USD | -37.7% |
| 2018 Q1 | -90.82 Million USD | -2.88% |
| 2017 Q3 | -77.13 Million USD | 7.16% |
| 2017 Q4 | -88.28 Million USD | -14.45% |
| 2017 FY | -314.67 Million USD | -58.55% |
| 2017 Q1 | -66.16 Million USD | -17.14% |
| 2017 Q2 | -83.08 Million USD | -25.57% |
| 2016 Q1 | -23.19 Million USD | 42.89% |
| 2016 Q2 | -55.95 Million USD | -141.2% |
| 2016 Q3 | -62.83 Million USD | -12.3% |
| 2016 FY | -198.47 Million USD | -68.58% |
| 2016 Q4 | -56.48 Million USD | 10.1% |
| 2015 FY | -117.73 Million USD | -120.04% |
| 2015 Q3 | -40.25 Million USD | -26.21% |
| 2015 Q2 | -31.89 Million USD | -543.47% |
| 2015 Q1 | -4.95 Million USD | 81.41% |
| 2015 Q4 | -40.62 Million USD | -0.91% |
| 2014 Q3 | 3.7 Million USD | 120.24% |
| 2014 FY | -53.5 Million USD | -22.8% |
| 2014 Q4 | -26.66 Million USD | -819.87% |
| 2014 Q1 | -12.24 Million USD | 1.08% |
| 2014 Q2 | -18.29 Million USD | -49.38% |
| 2013 Q4 | -12.38 Million USD | -5.43% |
| 2013 Q1 | -9.02 Million USD | 49.57% |
| 2013 Q2 | -10.41 Million USD | -15.43% |
| 2013 Q3 | -11.74 Million USD | -12.73% |
| 2013 FY | -43.56 Million USD | -59.64% |
| 2012 FY | -27.29 Million USD | 0.0% |
| 2012 Q4 | -17.89 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -129.794% |
| Dynavax Technologies Corporation | -6.38 Million USD | -5410.847% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 26854.407% |
| Perrigo Company plc | -12.7 Million USD | -2672.346% |
| Illumina, Inc. | -1.16 Billion USD | 69.674% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 105.873% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 20.708% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 95.923% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 125.927% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -218.462% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 108.906% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -783.312% |
| Waters Corporation | 642.23 Million USD | 154.822% |
| Biogen Inc. | 1.16 Billion USD | 130.324% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -36.558% |
| Evolus, Inc. | -61.68 Million USD | -470.784% |
| Adicet Bio, Inc. | -142.65 Million USD | -146.806% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -197.088% |
| bluebird bio, Inc. | -211.91 Million USD | -66.147% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -68.263% |
| FibroGen, Inc. | -284.23 Million USD | -23.873% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 128.394% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -689.376% |
| Homology Medicines, Inc. | -53.74 Million USD | -555.133% |
| Geron Corporation | -184.12 Million USD | -91.22% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 20.024% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -132.273% |
| Myriad Genetics, Inc. | -112 Million USD | -214.364% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -309.905% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 26.83% |
| Zoetis Inc. | 2.34 Billion USD | 115.021% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -549.753% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 144.637% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 310.02% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 109.727% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -734.352% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 3.876% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -27.51% |
| Verastem, Inc. | -87.36 Million USD | -302.999% |
| Nektar Therapeutics | -276.05 Million USD | -27.542% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -47.171% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -297.925% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 34.309% |
| OPKO Health, Inc. | -188.86 Million USD | -86.425% |
| Exelixis, Inc. | 207.76 Million USD | 269.465% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 241.004% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 431.72% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -641.16% |
| uniQure N.V. | -308.47 Million USD | -14.137% |
| Imunon, Inc. | -19.51 Million USD | -1704.194% |
| Blueprint Medicines Corporation | -506.98 Million USD | 30.552% |
| Insmed Incorporated | -749.56 Million USD | 53.028% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 225.034% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2878.472% |
| Incyte Corporation | 597.59 Million USD | 158.917% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 53.703% |